In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor  by Feleszko, Wojciech et al.
Correspondence
In vitro antitumor activity of
cerivastatin, a novel and potent
HMG-CoA reductase inhibitor
Wojciech Feleszkoa;b;*, Izabela Mlynarczuka;c, Dominika
Nowisa
First published online 3 August 2001
Angiogenesis, the growth of new blood vessels from a pre-
existing microvascular bed, is of crucial importance for the
growth, maintenance, and metastasis of solid tumors. Various
anti-angiogenic factors are currently being investigated, indi-
cating that angiogenesis may soon become a suitable target
for novel antitumor therapies. However, most of the currently
available potent angiostatic factors (angiostatin, endostatin)
are small protein fragments and their clinical application
may be associated with an unusual cost expense. In their
recent report Vincent and colleagues [1] demonstrate an inter-
esting, anti-angiogenic activity of 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor (HMG-CoA RI), cerivastatin.
Inhibitors of HMG-CoA reductase (or statins) represent a
newly discovered family of chemically related molecules, se-
lected for their lipid-lowering e¡ect. Statins are extensively
used in medical practice, and large clinical trials have demon-
strated that this class of lipid-lowering drugs greatly reduces
cardiovascular-related morbidity and mortality in patients
with and without coronary disease ([2] ; for review see [3]).
According to recent studies, the bene¢cial e¡ect of statins
may also be attributed to their favorable e¡ects on vascula-
ture [3].
In fact, we have demonstrated for the ¢rst time that lova-
statin, another HMG-CoA RI, inhibits angiogenesis, and this
e¡ect was due to the decreased production of VEGF imposed
by lovastatin in tumor cells [4]. Interestingly, the results of our
study and the recent paper of Vincent et al. do not match that
of Kureishi et al. [5], who show that statins promote angio-
genesis. This discrepancy most likely depends of the type of
the examined cells and the di¡erence of the experimental mod-
el used. In our study, lovastatin e¡ectively suppressed VEGF
production by tumor cells harboring ras mutations. This re-
sulted in the inhibition of bloodvessel formation, and ¢nally
in the retardation of tumor growth. These results suggest sta-
tin’s remarkable anti-angiogenic and antitumor e¡ects, partic-
ularly towards tumors harboring ras mutations.
Until recently, the bene¢cial antitumor e¡ects of treatment
with statins have been attributed only to their direct antipro-
liferative e¡ects on tumor cells. Evidence was provided that
statins induce cell cycle block in the G1 phase, interfere with
the function of the Ras oncoprotein, and induce a potent
apoptotic response. Some of the statins are being tested in
clinical trials as potential novel antitumor agents, as they
have been widely used and have well-de¢ned pharmaco-
kinetics at the clinical level, displaying negligible adverse
side e¡ects. Strikingly, a large clinical trial with lovastatin (a
total of 6605 patients), designed to study prevention of acute
coronary events with lovastatin, demonstrates a signi¢cant
reduction in the incidence of melanoma among lovastatin-
treated patients [2].
The results of our previous study [4] and the paper of Vin-
cent et al. [1] underline the feasibility of utilizing statins as
anti-angiogenic agents in tumor therapy, especially if it is
taken into account that they may be safely used to in£uence
tumor bloodvessels on a daily basis at levels well below the
maximum tolerated dose. Cerivastatin may be of particular
interest, since it possesses superior lipid-lowering activity at
doses equivalent to 1^3% of the doses of other statins (for
review see [6]). Although recent reports showed that ceriva-
statin exerts the most potent antiproliferative activity in com-
parison to simvastatin, lovastatin and atorvastatin against
smooth muscle and endothelial cells, no data exist yet about
its direct antiproliferative activity against tumor cells. In order
to further evaluate the antiproliferative e¡ects of cerivastatin
on tumor cell growth, we compared its cytostatic/cytotoxic
activity against various tumor cells to that exerted by lova-
statin and simvastatin.
We tested our hypothesis in a standard 3-[4,5-dimethyl-
thiazol-2-yl]diphenyltetrazolium bromide assay (MTT) which
was successfully applied in our previous studies [4]. In this
study we tested cerivastatin on a panel of human and murine
tumor cell lines, as shown in Table 1. The results of these
experiments were plotted as dose^response curves and then
subjected to median e¡ect analysis using the CalcuSyn soft-
ware (Biosoft, www.biosoft.com). Subsequently, the IC50 val-
ues (fraction of a¡ected cells = 0.5) were calculated for each
drug and cell line.
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Fig. 1. Dose^response curves: e¡ects of lovastatin, simvastatin, ceri-
vastatin with or without mevalonic acid, on C26 colon adenocarci-
noma cells in vitro. One-day-old monolayers of tumor cells were ex-
posed to increasing concentrations (0.625^2 Wg/ml) of lovastatin (F),
simvastatin (R), cerivastatin alone (b) or cerivastatin plus meva-
lonic acid (100 WM) (a) for 72 h. Cytostatic/cytotoxic e¡ects, ex-
pressed as percent control growth (% of untreated control), were
tested in an MTT assay. Each point represents the mean determined
for quadruplicate samples ( þ S.D.). *P6 0.05; **P6 0.001 (Stu-
dent’s t-test) in comparison to lovastatin as reference compound.
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In our experiments all statins displayed a dose-dependent
cytostatic/cytotoxic e¡ect in the examined tumor cells (an ex-
ample of Colon-26 tumor cells is shown in Fig. 1). However,
incubation of tumor cells with cerivastatin resulted in stronger
inhibition of proliferation as compared with lovastatin or sim-
vastatin. This e¡ect was statistically signi¢cant (Fig. 1). More-
over, the antiproliferative e¡ect of cerivastatin on tumor cells
was fully reversible by co-incubation with mevalonic acid,
implying that cerivastatin’s e¡ect is the direct consequence
of its ability to inhibit HMG-CoA reductase.
The antiproliferative activity of cerivastatin tested in vitro
on a panel of murine and human cell lines is shown in Table
1. In this set of cell lines, cerivastatin inhibited cell growth of
all lines with IC50 values ranging from 22 nM to 18.15 WM.
Lovastatin was used as reference compound to compare the
cytostatic/cytotoxic activity of cerivastatin. In vitro cerivasta-
tin was 2.5^55 times more e¡ective than lovastatin or simva-
statin tested in the same tumor cell model. It has not been
particularly e¡ective and more speci¢c against tumor cells
harboring ras mutations.
Our results con¢rm previous observations, indicating the
strong antiproliferative activity of cerivastatin [6]. In those
studies cerivastatin was demonstrated to e¡ectively inhibit
proliferation of smooth muscle cells, endothelial cells and
myoblasts in vitro, at IC50 = 0.04^0.06 WM [6]. In our experi-
ments tumor cells required higher concentrations of cerivasta-
tin than previously demonstrated in non-transformed cells.
However, this e¡ect was not identical and relied probably
on the tissue source of the tumor cells.
Cerivastatin, unlike lovastatin and simvastatin, is an open
ring, active form drug and belongs to the third generation
HMG-CoA RI. Existing data indicate that cerivastatin is
the most potent HMG-CoA reductase inhibitor amongst all
reported statins. While all therapeutically used statins express
their pharmacodynamic activity only in the mg range, ceriva-
statin’s cholesterol-lowering activity is achieved in the Wg
range, which may o¡er an ultra-low dose therapy to hyper-
cholesterolemic patients.
In conclusion, we have demonstrated a strong inhibitory
e¡ect of cerivastatin against tumor cells in extremely low
doses. One may speculate that the pleiotropic e¡ects of ceri-
vastatin, including its potent anti-angiogenic activity, may
contribute to its potential antitumor e¡ects. These data high-
light the potential of cerivastatin to include supplementation
of tumor therapy. Similarly to lovastatin and simvastatin, the
combination of cerivastatin with standard chemotherapeutic
agents may be investigated for the potential improvement of
the outcomes in the management of cancer. To our knowl-
edge, this report is the ¢rst to demonstrate the potent cyto-
static/cytotoxic e¡ects of cerivastatin against tumor cells.
However, further studies are warranted for the application
of cerivastatin as a novel approach to the treatment of cancer.
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Table 1
Inhibitory e¡ects of lovastatin, simvastatin and cerivastatin on in vitro growth of tumor cells
Cell line Tissue Species ras status Cell growth assay IC50 (WM)a
cerivastatin lovastatin simvastatin cerivastatin/lovastatin
ratio
B16F10 melanoma mouse wild-type ras 1.92 5.15 3.89 0.37
C26 colon adenocarcinoma mouse unknown 0.84 5.94 4.01 0.14
EL-4 lymphoma mouse unknown 0.022 0.057 0.080 0.38
HBL-ras Ha-ras-transformed mammary human Ha-ras 2.18 8.84 4.69 0.24
OVCA-1 ovary, adenocarcinoma human unknown 4.5 34.12 15.94 0.13
PANC-1 pancreas carcinoma human Ki-ras 9.57 138.94 122.09 0.07
Ras-3T3 Ha-ras-transformed ¢broblasts mouse Ha-ras 0.082 4.57 1.37 0.017
T24 bladder carcinoma human Ha-ras 1.2 8.79 7.33 0.14
U937 histiocytic lymphoma human unknown 2.01 149.21 20.52 0.01
One-day-old monolayers of tumor cells were exposed to various concentrations of lovastatin, simvastatin or cerivastatin. Cytostatic/cytotoxic ef-
fects, expressed as percent control growth (% of untreated control), were tested in an MTT assay and subjected to median e¡ect analysis using
CalcuSyn software.
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